Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2006

View Archived Issues

EAGLE study of Axxion stent meets primary endpoint

NicOx signs new ophthalmology agreement with Pfizer

Takeda selects cardiovascular target from Lexicon alliance

Nonapprovable letter for Emezine

Nastech reacquires rights to PYY3-36 nasal spray from Merck

Applied Biosystems completes acquisition of Ambion's Research Products Division

Keryx studies KRX-0401 for refractory leukemias

Sangamo licenses use of MaxCyte's cell loading system

Evizon 40 mg safe and active in stabilizing vision in wet AMD

Ganite effective compared with Aredia in cancer-related hypercalcemia

Oral NV-52 demonstrates rapid absorption and appreciable plasma levels

Endocannabinoid-derived topical treatment for atopic dermatitis

New inhibitor of PDGFR autophosphorylation for cell-proliferative disorders

Lucentis submitted for European approval for wet AMD

Novartis seeks European approval for Exforge

Priority review for Revlimid sNDA

Novel antiinfective agents covered in recent patents

Neupro receives approvable letter for early Parkinson's disease

Monoclonal antibody induces regression of HGF-dependent tumors in mice

Recent Pfizer, Gruenenthal and AstraZeneca patents report novel analgesic agents

Recent patents report novel agents for metabolic disorders

Clinical study of pollen extract preparation in CNBP/CPPS

R-850 shows good safety and efficacy profile in actinic keratosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...